Egoropal

GIF decision: Marketing suspension

What does this decision mean?

  • Wstrzymanie w obrocie — The product has been temporarily suspended from circulation — sales are paused pending clarification, but it is not a full market recall.

A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes. The risk assessment indicated a high risk to product quality and patient safety for aseptically filled batches available on the market. Potential effects: infection, sepsis, serious complications, lack of treatment efficacy.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Egoropal
Risk Level
Critical
Manufacturer
Egis Pharmaceuticals PLC z siedzibą w Budapeszcie, Węgry
Batch Number
4400718, 4500766, 4501274, 4400293, 4400851, 4500598, 4500832, 4500892, 4501060, 4501376
Notice Date
23.12.2025
View official statement

Related

Other Notices